Aisling Capital related stories
All articles and analysis
VC-backed Menlo Therapeutics goes publicMenlo Park, California-based Menlo Therapeutics Inc, a pharmaceutical company focused on treating chronic pruritus and chronic cough, has raised $119 million for its IPO after pricing its 7 million shares at $17 per share. The stock began trading January 25, 2018 on the NASDAQ under the ticker symbol "MNLO." Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities LLC are the lead underwriters. The investors included VenBio, Novo Holdings A/S, Rock Springs Capital, Aisling Capital, Bay City Capital, Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital.
Aisling Capital raises $280mThe New York-based biotech VC closes $120m shy of initial target.
- Aisling Capital raises $280 mln for fund
Aisling Capital, a late-stage life sciences investment firm, has closed its latest fund at $280 million. The fund will focus on "helping clinical stage ventures improve global health."
- BioScience Managers adds three directors to team
Melbourne, Australia-based healthcare investment firm BioScience Managers Limited has appointed Dr. Michael Perry as a director, Dennis Purcell as a director and senior expert adviser and Nicole Vitullo as an independent director. Perry was senior vice president and chief scientific officer (business development and licensing) for Novartis AG while Purcell is a founder and former senior managing partner of Aisling Capital. And, Vitullo is a partner at life sciences venture firm Domain Associates LLC.
- BridgeBio Pharma nets $135 mln
Palo Alto, California-based BridgeBio Pharma, a clinical-stage biopharmaceutical company, has raised $135 million in funding. Viking Global Investors and KKR led the round with participation from Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital and Janus Funds.
